of renal autoregulation. In animal models, this autoregulatory impairment is associated with a relative lack of renal protection compared with the magnitude of blood pressure reduction observed. 5, 6 Consequently, there is a failure to maximally protect against renal parenchymal changes with such agents unless systolic blood pressure is lowered well below the range of 100-105 mm Hg. 7 In contrast, T-type calcium channels are expressed in both the afferent (preglomerular) and the efferent (postglomerular) arterioles, 8 and hence, their inhibition may overcome the effect of increased glomerular pressure transmission, as both arterioles would be dilated in the additional presence of renin-angiotensin system blockade. Efonidipine is a dihydropyridine T-type calcium channel antagonist that has been extensively studied in regard to renal hemodynamics 9 and, in rat models, demonstrated significantly greater reduction in intraglomerular pressure and proteinuria than L-channel dihydropyridine despite similar blood pressurelowering effects. 10, 11 The study by Sugano and colleagues 12 (this issue) adds to our understanding of the factors that contribute to changes within the renal vasculature in a rat model of renal insufficiency by both efonidipine and the R(-) isomer of efonidipine. The authors confirm that blockade of the T-type calcium channel confers a greater hemodynamic protection on the renal Calcium antagonists comprise two main subclasses, dihydropyridines and nondihydropyridines. They inhibit two types of voltage-dependent channels: a high voltage-activated calcium channel including P-/Q-, L-, N-, and R-type channels, and a low voltage-activated T-type channel. Calcium antagonists modulate various calcium-dependent functions of vascular smooth muscle throughout the body as well as cardiac myocytes and the conductive tissues of the heart. The distribution of these channels varies throughout the vasculature and results in differences in kidney function when inhibited ( Figure 1 ). These differences account, in part, for some of the observed clinical differences in antiproteinuric response and relative degrees of tissue protection. [1] [2] [3] [4] Nifedipine, diltiazem, and verapamil serve as the prototypic agents for the dihydropyridine, benzothiazepine, and phenylalkylamine classes of L-channel calcium antagonists, respectively. The L channel is located primarily on the afferent (preglomerular) arteriole and hence, when antagonized, results in impairment microvasculature than the L-type calcium channel blockade and extend our previous knowledge by demonstrating non-hemodynamic effects of this agent, including inhibition of Rho-kinase activity in response to transforming growth factor-β, reduced tubulointerstitial fibrosis, and epithelial-mesenchymal transition. This study further distinguishes efonidipine as a calcium antagonist with not only a unique hemodynamic profile but also cellular effects not seen with other dihydropyridine agents in the class. 13 Although the L-channel dihydropyridine calcium antagonists have been extensively studied in humans with regard to proteinuric kidney disease progression, they have failed to show the outcome benefit noted with blockers of the renin-angiotensinaldosterone system. 2, 14 Moreover, the benefit of the dihydropyridine calcium antagonists in this setting is not as great as that of the non-dihydropyridine agents. 2 An early systematic review reported by Kloke et al. showed that calcium antagonists are effective antihypertensive agents but are of uncertain value in patients with proteinuria and elevated creatinine. 15 In subsequent randomized blinded outcome trials of people with proteinuric kidney disease, progressive increases in proteinuria and a more rapid decline in kidney function were noted in patients treated with dihydropyridine calcium antagonists compared with those treated with angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers. 16, 17 In the African American Study of Kidney Disease and Hypertension and the Irbesartan Diabetic Nephropathy Trial, the dihydropyridine calcium antagonist amlodipine failed to slow decline in kidney function or mitigate increases in proteinuria in patients with hypertension and proteinuric nephropathy as compared with an ACE inhibitor or angiotensin receptor blocker regimen. 16, 17 A recent systematic review of 28 randomized trials evaluating renal outcomes in hypertensive patients with or without diabetes found similar blood pressure lowering with differences in antiproteinuric effects between dihydropyridine and non-dihydropyridine calcium antagonists. 2 Analysis of the blood pressure co mmentar y data (n = 1,338) and kidney function data (n = 510) showed significant differences in proteinuria reduction between groups (+2% with dihydropyridines versus -30% with non-dihydropyridines, P = 0.01). After adjustment for blood pressure, sample size, and study duration, a trend persisted in favor of proteinuria reduction for the non-dihydropyridines. A secondary analysis supported the benefit for nephropathy progression of non-dihydropyridines with or without concurrent ACE inhibitor or angiotensin receptor blocker therapy. 2 Unfortunately, very few human studies have been done with the T-type channel calcium antagonists, and currently no clinical outcome data exist. The largest randomized human study to date is an open-label prospective trial that evaluated 68 hypertensive patients with chronic kidney disease, that is, serum creatinine greater than 1.5 mg/dl over the span of 48 weeks. The authors compared the effects on blood pressure and proteinuria reduction of the dihydropyridine T-type calcium channel antagonist efonidipine (mean dose of 38 mg per day at study's end) versus various ACE inhibitor monotherapy treatments (mean dose of enalapril, lisinopril, and imidapril was 8 mg per day, 11 mg per day, and 5 mg per day, respectively, at study's end). 10 Both classes of antihypertensive agents reduced blood pressure and urinary protein excretion to a similar extent in a cohort of patients with a baseline proteinuria greater than 1 g per day. This preliminary observation indicates that efonidipine may also slow progression of proteinuric kidney disease to an extent similar to that achieved by ACE inhibitors, although this needs confirmation in future clinical studies. A fixed-dose combination of efonidipine with a blocker of the renin-angiotensin system may provide an additional tool in the armamentarium to treat hypertensive proteinuric kidney disease since each agent has complementary intra-renal hemodynamic as well as systemic blood pressure lowering effects. All this needs confirmation in randomized clinical trials.
Efonidipine is used primarily in Japan and has not been available in the United States, Australia, or Europe. It should be appreciated, however, that there are differential benefits for proteinuria reduction with non-dihydropyridine relative to dihydropyridine agents in the subset of patients with advanced proteinuric kidney disease. This differential effect may result in a slower decline in kidney function, 2,14 although this has not been proven. On the basis of the recommendations of the Kidney Disease Outcomes Quality Initiative (KDOQI) blood pressure and diabetes guidelines, non-dihydropyridine calcium antagonists in conjunction with an ACE inhibitor or angiotensin receptor blocker are preferable in hypertensive patients with proteinuria greater than 300 mg per day, as well as those with impaired kidney function. 18, 19 
